Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Background rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-
based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested …

Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …

Ebola virus (EBOV) is considered one of the most aggressive infectious agents and is
capable of causing death in humans and nonhuman primates (NHPs) within days of …

Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high
fatality rates. These viruses pose a significant health concern worldwide due to the lack of …

In 1967, the first reported filovirus hemorrhagic fever outbreak took place in Germany and
the former Yugoslavia. The causative agent that was identified during this outbreak, Marburg …

Background Safe and effective vaccines against Ebola could prevent or control outbreaks.
The safe use of replication-competent vaccines requires a careful dose-selection process …

The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high
mortality rate in humans and nonhuman primates. Among the most-promising filovirus …

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …